| __timestamp | Bio-Techne Corporation | Wave Life Sciences Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 60716000 | 2999000 |
| Thursday, January 1, 2015 | 119401000 | 10393000 |
| Friday, January 1, 2016 | 140879000 | 15994000 |
| Sunday, January 1, 2017 | 199243000 | 26975000 |
| Monday, January 1, 2018 | 240636000 | 39509000 |
| Tuesday, January 1, 2019 | 264359000 | 48869000 |
| Wednesday, January 1, 2020 | 260583000 | 42510000 |
| Friday, January 1, 2021 | 324951000 | 46105000 |
| Saturday, January 1, 2022 | 372766000 | 50513000 |
| Sunday, January 1, 2023 | 378378000 | 51292000 |
| Monday, January 1, 2024 | 396826000 |
Cracking the code
In the ever-evolving biotech industry, operational costs, particularly Selling, General, and Administrative (SG&A) expenses, are crucial indicators of a company's financial health. Over the past decade, Bio-Techne Corporation has consistently outpaced Wave Life Sciences Ltd. in SG&A spending, reflecting its expansive growth and market presence. From 2014 to 2023, Bio-Techne's SG&A expenses surged by over 550%, peaking in 2023, while Wave Life Sciences saw a more modest increase of approximately 1,600% during the same period. This disparity highlights Bio-Techne's aggressive investment in operational infrastructure compared to Wave Life Sciences' more conservative approach. Notably, data for 2024 is incomplete, suggesting potential shifts in strategy or reporting. As the biotech landscape continues to evolve, these trends offer valuable insights into the strategic priorities and financial management of these industry players.
Eli Lilly and Company and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared
Novartis AG or Bio-Techne Corporation: Who Manages SG&A Costs Better?
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: SG&A Expense Trends
Bio-Techne Corporation vs Rhythm Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Bio-Techne Corporation or Bausch Health Companies Inc.
Breaking Down SG&A Expenses: Bio-Techne Corporation vs Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Bio-Techne Corporation or Taro Pharmaceutical Industries Ltd.
Selling, General, and Administrative Costs: Bio-Techne Corporation vs Evotec SE
Lantheus Holdings, Inc. and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and Wave Life Sciences Ltd.
Selling, General, and Administrative Costs: Protagonist Therapeutics, Inc. vs Wave Life Sciences Ltd.
Mesoblast Limited and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared